XENON PHARMACEUTICALS INC (XENE) Stock News

USA - Nasdaq - NASDAQ:XENE - CA98420N1050 - Common Stock

43.6 USD

-0.46 (-1.04%)

Last: 12/15/2025, 8:00:03 PM

43.74 USD

+0.14 (+0.32%)

Pre-Market: 12/16/2025, 5:41:09 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XENE Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: The Motley Fool - Mentions: CYTK PHVS MAZE LYEL

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

11 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

11 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

12 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Benzinga

Insights into Xenon Pharmaceuticals's Upcoming Earnings

12 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 days ago - By: Zacks Investment Research - Mentions: MIRM

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

13 days ago - By: The Motley Fool - Mentions: HNGE CAI CGON NBIX ...

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock

13 days ago - By: Zacks Investment Research - Mentions: BMRN

Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?

13 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

13 days ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

21 days ago - By: Xenon Pharmaceuticals Inc.

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

21 days ago - By: Xenon Pharmaceuticals Inc.

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

a month ago - By: Xenon Pharmaceuticals Inc.

Xenon to Present at Upcoming Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: BEAM NBIX FOLD

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

a month ago - By: Xenon Pharmaceuticals Inc.

Xenon Reports Third Quarter 2025 Financial Results & Business Update

a month ago - By: Xenon Pharmaceuticals Inc.

Xenon Reports Third Quarter 2025 Financial Results & Business Update

2 months ago - By: Xenon Pharmaceuticals Inc.

Xenon to Report Q3 2025 Financial Results on November 3, 2025

a month ago - By: Benzinga - Mentions: ON TIMB GT IRMD ...

Earnings Scheduled For November 3, 2025

2 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

2 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

2 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

3 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

3 months ago - By: Design Therapeutics, Inc. - Mentions: DSGN CMPS

Design Therapeutics Appoints Justin Gover to Board of Directors

3 months ago - By: Zacks Investment Research - Mentions: NTLA

Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?

4 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Zacks Investment Research - Mentions: NBIX CRMD ALVO

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus